This was an expected finding, since EDS and daytime sleep attacks are the defining symptoms for narcolepsy.[14,21,22] No significant association was found between the somnolent narcoleptic symptoms and the CNS stimulant medication status of the NIQ respondents.
The majority of medicated narcoleptic respondents were taking a CNS stimulant, as expected, considering the pervasiveness of EDS.
These stimulants act to increase the amount of monoamines (epinephrine, norepinephrine, dopamine and serotonin) available within the synaptic cleft of synapses located primarily in the dopamine systems of the CNS. Indirect sympathomimetic drugs are potent CNS stimulants. The stimulating effects include increased wakefulness, alertness, decreased fatigue, elevation of mood, increased motor activity and reduced proportion of REM sleep. While chemically similar, the relative effects of these stimulant drugs are highly variable in humans.
The drug classes used for analysis included: CNS stimulants, caffeine stimulants, tricyclic antidepressants and experimental drugs.
(*) 419 respondents reported taking some type of narcoleptic medication; 377 and 116 respondents were taking CNS stimulants and tricyclic antidepressants, respectively.
Using extensive chart reviews of medical histories, we identified two groups of patients: those reporting a "significant positive response" to CNS stimulants, and those reporting a "significant negative response" as we define in our methods below.
Prefrontal pole activation may indicate the brain's ability to allocate attentional resources, as some brains appear to be shutting down these resources when forced to concentrate: It is these brains that seem to do well on CNS stimulants. Brains that allocate attentional resources ostensibly do not.
Finally, we did not differentiate among CNS stimulants, in spite of their having somewhat differential effects on the brain (Challman & Lipsky 2000).
Summary: Depression Drugs Market research report categorizes the global market by Drug Class (Atypical antipsychotics, Serotonin-norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, CNS stimulants, Others), By Disease Type (Major Depressive Disorder, Schizophrenia and bipolar I disorder, SSRI induced, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, MEA)
Browse Full report on Market with TOC: https://www.factmr.com/report/3215/depression-drugs-market Depression Drugs Market: Segment-wise Insights On the basis of drug class, the global depression drugs market has been segmented into SSRIs, atypical antipsychotics, SNRIs, CNS stimulants, and others.
Observe patients carefully when amantadine is used concurrently with other drugs that affect the CNS, especially CNS stimulants
. Concomitant antihistamines or anticholinergic drugs may increase CNS reactions.